Target type: biologicalprocess
Any process that activates or increases the frequency, rate or extent of macrophage migration. [GO_REF:0000058, GOC:TermGenie, PMID:25749876]
Positive regulation of macrophage migration is a complex process that involves a series of coordinated events, ultimately leading to the directed movement of macrophages towards a specific target. This process is essential for various physiological functions, including wound healing, immune responses, and tissue repair.
**Key factors involved in positive regulation of macrophage migration:**
**1. Chemokines:** These are small signaling molecules that act as chemoattractants, guiding macrophages towards the site of inflammation or injury. Chemokines bind to specific receptors on the macrophage surface, triggering intracellular signaling cascades that initiate migration. Examples of chemokines involved in macrophage migration include CCL2, CCL3, CCL5, and CXCL8.
**2. Cytokines:** These are proteins secreted by cells that influence the behavior of other cells. Cytokines like TNF-α, IL-1β, and IFN-γ can promote macrophage migration by inducing the expression of chemokine receptors and other migration-related molecules.
**3. Extracellular matrix (ECM) components:** Macrophages interact with the ECM, a network of proteins and polysaccharides that provides structural support and regulates cell behavior. Specific ECM components, such as fibronectin and collagen, can act as adhesive substrates, guiding macrophage movement.
**4. Integrins:** These are cell surface receptors that mediate cell-cell and cell-ECM interactions. Integrins bind to ECM components and trigger signaling pathways that regulate cytoskeletal organization and cell motility.
**5. Rho GTPases:** These are small signaling proteins that control cytoskeletal dynamics and cell migration. Activation of specific Rho GTPases, such as Rac1 and Cdc42, promotes the formation of lamellipodia and filopodia, which are protrusions that drive macrophage movement.
**6. Intracellular signaling pathways:** Various signaling pathways, including the MAPK, PI3K, and AKT pathways, are activated downstream of chemokine and ECM receptor engagement. These pathways regulate gene expression, cytoskeletal remodeling, and other processes that contribute to macrophage migration.
**7. Polarization and chemotaxis:** During migration, macrophages become polarized, with one end of the cell leading the way (the leading edge) and the other trailing behind (the trailing edge). This polarization allows for directed movement towards the chemoattractant gradient.
**8. Actin polymerization and depolymerization:** Actin filaments are the primary components of the cytoskeleton, and their assembly and disassembly drive the extension and retraction of cell protrusions. Precise control of actin dynamics is essential for macrophage migration.
**9. Microtubule dynamics:** Microtubules are another component of the cytoskeleton that plays a role in regulating cell polarity and directional movement.
**10. Vesicular trafficking:** Macrophages rely on vesicular trafficking to transport proteins and other molecules to the leading edge of the cell, supporting migration.
**Overall, positive regulation of macrophage migration is a complex and highly regulated process involving a coordinated interplay of signaling molecules, ECM components, cytoskeletal proteins, and intracellular signaling pathways. This intricate mechanism ensures that macrophages can effectively navigate to sites of injury or infection, contributing to tissue repair, immune surveillance, and other critical physiological functions.**'
"
Protein | Definition | Taxonomy |
---|---|---|
Matrix metalloproteinase-14 | A matrix metalloproteinase-14 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P50281] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
tiludronic acid | tiludronic acid: a bone resorption inhibitor; an antihypercalcemic agent; used in the tratment of Paget's disease; used in the treatment and prevention of osteoporosis; structure given in first source | organochlorine compound | |
epigallocatechin gallate | (-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin. epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis) | flavans; gallate ester; polyphenol | antineoplastic agent; antioxidant; apoptosis inducer; geroprotector; Hsp90 inhibitor; neuroprotective agent; plant metabolite |
zoledronic acid | zoledronic acid : An imidazole compound having a 2,2-bis(phosphono)-2-hydroxyethane-1-yl substituent at the 1-position. Zoledronic Acid: An imidobisphosphonate inhibitor of BONE RESORPTION that is used for the treatment of malignancy-related HYPERCALCEMIA; OSTEITIS DEFORMANS; and OSTEOPOROSIS. | 1,1-bis(phosphonic acid); imidazoles | bone density conservation agent |
marimastat | marimastat : A secondary carboxamide resulting from the foraml condensation of the carboxy group of (2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoic acid with the alpha-amino group of N,3-dimethyl-L-valinamide. marimastat: a matrix metalloproteinase inhibitor active in patients with advanced carcinoma of the pancreas, prostate, or ovary | hydroxamic acid; secondary carboxamide | antineoplastic agent; matrix metalloproteinase inhibitor |
ilomastat | CS 610: matrix metalloproteinase inhibitor; structure in first source ilomastat : An N-acyl-amino acid obtained by formal condensation of the carboxy group of (2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoic acid with the amino group of N-methyl-L-tryptophanamide. A cell permeable broad-spectrum matrix metalloproteinase (MMP) inhibitor | hydroxamic acid; L-tryptophan derivative; N-acyl-amino acid | anti-inflammatory agent; antibacterial agent; antineoplastic agent; EC 3.4.24.24 (gelatinase A) inhibitor; neuroprotective agent |
cgs 27023a | CGS 27023A: a matrix metalloproteinase inhibitor | ||
prinomastat | prinomastat : A hydroxamic acid that is (3S)-N-hydroxy-2,2-dimethylthiomorpholine-3-carboxamide in which the hydrogen attached to the thiomorpholine nitrogen has been replaced by a [4-(pyridin-4-yloxy)phenyl]sulfonyl group. It is a selective inhibitor with of matrix metalloproteinases (MMPs) 2, 3, 9, 13, and 14. prinomastat: a diazepine-based hydroxamic acid inhibitor; matrix metalloproteinase (MMP) inhibitor; angiogenesis inhibitor; | aromatic ether; hydroxamic acid; pyridines; sulfonamide; thiomorpholines | antineoplastic agent; EC 3.4.24.35 (gelatinase B) inhibitor; matrix metalloproteinase inhibitor |
rs-130830 | RS-130830: orally-active broad-spectrum matrix metalloproteinase inhibitor | ||
tmi-1 | |||
batimastat | batimastat : A secondary carboxamide resulting from the formal condensation of the carboxy group of (2S,3R)-5-methyl-3-{[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]carbamoyl}-2-[(thiophen-2-ylsulfanyl)methyl]hexanoic acid with the amino group of hydroxylamine. It a broad-spectrum matrix metalloprotease inhibitor. batimastat: structure given in first source; a synthetic matrix metalloproteinase inhibitor | hydroxamic acid; L-phenylalanine derivative; organic sulfide; secondary carboxamide; thiophenes; triamide | angiogenesis inhibitor; antineoplastic agent; matrix metalloproteinase inhibitor |
ik 682 | IK 682: inhibits TNF-alpha converting enzyme; structure in first source | hydroxamic acid; pyrrolidin-2-ones; quinolines | |
epigallocatechin-3-o-(3''-o-methyl)-gallate | catechin | ||
ro 32-3555 | Ro 32-3555: structure given in first source | ||
sb 3ct compound | SB 3CT compound: a matrix metalloproteinase-2 inhibitor; structure in first source | aromatic ether | |
pd 166793 | |||
sc 78080 | |||
ro 31-9790 | Ro 31-9790: hydroxamic acid derivative | ||
arp-100 | |||
kb r8301 | |||
N(2)-([biphenyl]-4-ylsulfonyl)-N-hydroxy-N(2)-isopropoxy-D-valinamide | N(2)-([biphenyl]-4-ylsulfonyl)-N-hydroxy-N(2)-isopropoxy-D-valinamide : A hydroxamic acid that is N-hydroxy-D-valinamide in which the alpha-amino group has been substituted by isopropoxy and [biphenyl]-4-ylsulfonyl groups. A selective matrix metalloproteinase-2 (MMP-2) inhibitor, it is one of the most potent inducers of autophagy. Its physiological roles include angiogenesis, cancer metastasis, embryogenesis, tissue remodeling in development, and wound healing. | D-valine derivative; hydroxamic acid | antineoplastic agent; autophagy inducer; EC 3.4.24.24 (gelatinase A) inhibitor; melanin synthesis inhibitor |
bms-566394 | BMS-566394: structure in first source | ||
incb3619 | INCB3619: ADAM inhibitor; structure in first source | ||
6-(3,5-difluoroanilino)-9-ethyl-2-purinecarbonitrile | 6-aminopurines | ||
6-(3,5-difluoroanilino)-9-(2,2-difluoroethyl)-2-purinecarbonitrile | 6-aminopurines | ||
9-(3,5-difluorophenyl)-6-(ethylamino)-2-purinecarbonitrile | imidazoles | ||
grassystatin a | grassystatin A: isolated from a cyanobacterium, identified as Lyngbya cf.; structure in first source |